PKO Investment Management Joint Stock Co Invests $592,000 in Edwards Lifesciences Co. (NYSE:EW)

PKO Investment Management Joint Stock Co acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 8,000 shares of the medical research company's stock, valued at approximately $592,000.

Several other institutional investors also recently bought and sold shares of the company. Janney Montgomery Scott LLC increased its holdings in shares of Edwards Lifesciences by 0.7% in the 4th quarter. Janney Montgomery Scott LLC now owns 43,095 shares of the medical research company's stock valued at $3,190,000 after acquiring an additional 302 shares during the period. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth $266,000. Blue Trust Inc. boosted its position in shares of Edwards Lifesciences by 35.6% in the 4th quarter. Blue Trust Inc. now owns 10,914 shares of the medical research company's stock worth $808,000 after purchasing an additional 2,865 shares in the last quarter. Mount Yale Investment Advisors LLC boosted its position in shares of Edwards Lifesciences by 1.9% in the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company's stock worth $634,000 after purchasing an additional 162 shares in the last quarter. Finally, Strategic Blueprint LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth $203,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on EW shares. Royal Bank of Canada reissued an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Truist Financial lowered their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Piper Sandler raised their price objective on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 13th. Citigroup reaffirmed a "buy" rating and set a $95.00 price target (up previously from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Finally, Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $80.20.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,189,770.56. The trade was a 16.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total value of $797,287.50. Following the transaction, the chief financial officer now owns 30,387 shares in the company, valued at approximately $2,153,526.69. This represents a 27.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 59,012 shares of company stock worth $4,224,717. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded down $0.19 on Monday, hitting $78.03. The company's stock had a trading volume of 3,374,673 shares, compared to its average volume of 5,189,554. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The firm has a fifty day moving average price of $73.49 and a 200-day moving average price of $72.57. The company has a market capitalization of $45.77 billion, a price-to-earnings ratio of 11.20, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the previous year, the business earned $0.66 EPS. Edwards Lifesciences's revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.